Chronic lymphocytic leukemia Press Release
|04/21/2020 - 15:02||
U.S. FDA Approves IMBRUVICA (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
|04/08/2020 - 12:14||
New Prognostic Tool Helps Leukemia Patients Plan for Cancer Treatment
First validated prognostic score offers valuable insights for patients advised to ‘watch and wait’
|02/09/2020 - 19:59||
U.S. FDA Grants Priority Review for Kites KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
|01/28/2020 - 13:12||
European Medicines Agency Validates Kites Marketing Application for Companys Second CAR T Cell Therapy
Investigational KTE-X19 To Be First Chimeric Antigen Receptor (CAR) T Cell Therapy for Mantle Cell Lymphoma in Europe if Approved --
|12/09/2019 - 19:44||
Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), today announced primary results from ZUMA-2, a global, multicenter, single-arm, open-label Phase 2 study of KTE-X19, an investigational CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients with relapsed or refractory mantle cell lymphoma (MCL).
|12/09/2019 - 19:06||
City of Hope doctors present research on new immunotherapies at American Society of Hematology conference
Researchers also reveal a first-of-its-kind study on long-term health outcomes for bone marrow transplant survivors.
|City of Hope Na...|
|12/09/2019 - 11:18||
Xencor Presents Initial Data from Phase 1 Study of XmAb13676 in B-cell Malignancies at the ASH Annual Meeting
Data are being presented by Krish Patel, M.D., Director of the Lymphoma Program at Swedish Cancer Institute, in a poster session today from 6:00 p.m.
|12/09/2019 - 09:40||
ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
Eight of nine evaluable CLL patients initially dosed at ≥65 mg experienced a Partial Response (PR)
|12/08/2019 - 22:20||
New Mayo Clinic studies to be presented at American Society of Hematology meeting
ORLANDO, Fla. — Mayo Clinic researchers will present findings at the American Society of Hematology Annual Meeting Dec.
|12/08/2019 - 08:15||
New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia
In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia At four-year follow-up of the MURANO study, Venclexta/Venclyxto plus MabThera/Rituxan continued to reduce disease progression compared to a standard-of-care therapy in previously treated chronic lymphocytic leukaemia Data presented on both studies include results on minimal residual disease, which is currently emerging as a potential surrogate endpoint.
|12/07/2019 - 10:29||
Genentech Announces New Data on Novel CD20-CD3 Bispecific Cancer Immunotherapies in People With Difficult-to-Treat Lymphomas
Mosunetuzumab data to be presented at the American Society of Hematology 2019 Annual Meeting Plenary Scientific Session demonstrate durable complete responses in people with relapsed or refractory non-Hodgkin’s lymphoma.
|12/07/2019 - 09:02||
Calquence significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukaemia
Full results from the Phase III ELEVATE TN trial showed 93% of patients on Calquence combined with obinutuzumab vs.
|12/05/2019 - 16:15||
US Oncology Research Announces Schedule of Presentations at the 2019 American Society of Hematology Annual Meeting and Exposition
Top researchers will present abstracts on latest clinical research advancing cancer treatment options.
|12/03/2019 - 09:07||
CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications
CASI previously reported its acquisition of exclusive worldwide commercial rights to CNCT19 from Juventas. Juventas has responsibility for the clinical development of CNCT19.
|11/25/2019 - 14:17||
International collaboration yields insights into childhood leukemia risk
By joining forces, researchers at St. Jude Children’s Research Hospital and the Institute for Cancer Research UK have discovered new genetic variants associated with B-cell acute lymphoblastic leukemia risk.
|11/25/2019 - 10:53||
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
Conference call and webcast with ArQule management to be held on Monday, December 9, 2019 at 8:15 a.m.
|11/21/2019 - 13:09||
Fred Hutch at ASH: Latest CAR T data BCMA, CD19, CD20 plus new insights on transplantation, gene therapy and more
SEATTLE — Nov. 21, 2019 — Fred Hutchinson Cancer Research Center’s latest findings on CAR (chimeric antigen receptor) T-cell therapy, gene therapy, precision oncology, immune repair and transplantation will be featured at the 61st American Society of Hematology Annual Meeting and Exposition, which will be held Dec.
|11/21/2019 - 11:36||
Calquence approved in the US for adult patients with chronic lymphocytic leukaemia
Two Phase III Calquence trials demonstrated superior progression-free survival across multiple settings while maintaining favourable tolerability.
|11/21/2019 - 10:53||
FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukemia
Today, as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the U.S. Food and Drug Administration granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This new approved indication for Calquence provides a new treatment option for patients with CLL or SLL as an initial or subsequent therapy.
|11/20/2019 - 23:53||
Project Orbis: FDA approves acalabrutinib for CLL and SLL
On November 21, 2019, the Food and Drug Administration approved acalabrutinib (CALQUENCE, AstraZeneca) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
|11/06/2019 - 21:08||
Xencor to Present Initial Data from the Phase 1 Study of XmAb13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting
The most common treatment-related adverse event has been fever. Cytokine release syndrome, the second most common adverse event, has been generally manageable with premedication," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor.
|11/06/2019 - 17:16||
ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies
ARQ 531 demonstrates substantial anti-tumor activity in refractory CLL patients and manageable safety profile A total of 10 patients experienced partial responses (PRs) as of July 19th, the cutoff date for data included in the abstract, primarily at the higher doses: 7 with CLL/SLL, 1 with FL, 1 with Richter’s Transformation and 1 with DLBCL.
|11/06/2019 - 10:54||
Calquence data to show improved progression-free survival in Phase III front-line chronic lymphocytic leukaemia trial at ASH 2019 Annual Meeting
Robust early-stage pipeline advancements and presentations across multiple scientific platforms demonstrate potential to improve treatment outcomes in blood cancers with high unmet need
|10/03/2019 - 21:57||
MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies
These new data will be presented at MEI's Investor and Analyst Event being held tomorrow, October 4, 2019, at 8:00 am ET.
|10/01/2019 - 17:14||
A team effort uncovers how cancer outwits a targeted drug
Top, from left: Vivian Liu, Steve Carr, Vamsi Mootha. Bottom, from left: Romain Guièze, Cathy Wu, John Doench.